The global cell and gene therapy market size is estimated to grow from USD 14.2 billion in 2022 at 24% CAGR (2023-2032) to reach an estimated USD 117.1 billion by 2032, as a result of rising clinical trials and the increasing number of product approvals.
Unlock Infinite Advantages: Subscribe to Annual Membership
Unlock Infinite Advantages: Subscribe to Annual Membership
Oncology Accounts for the Most Active Therapeutic Segment Through All the Stages of Development.
The cell and gene therapy market is a rapidly growing sector within the healthcare industry that involves the use of cellular and genetic materials to treat various diseases and medical conditions. Cell therapy involves the transplantation or administration of live cells into a patient's body to restore or improve cellular function, while gene therapy involves the introduction or alteration of genetic material to treat genetic disorders or modify the function of cells.
Cell and gene therapies have the potential to revolutionize the treatment of a wide range of diseases. They can be used for conditions such as cancer, genetic disorders, cardiovascular diseases, neurodegenerative diseases, and autoimmune disorders, among others. This broad applicability enhances the market's growth potential.
Oncology continued to be the most active therapeutic area of research across all stages of development, including preclinical through preregistration. In the field of gene and cell therapy, there were more than 1,300 candidates reported in development specifically for oncology in 2021. This highlights the significant focus and investment in developing innovative therapies to address cancer and improve patient outcomes.
Collaborations, acquisitions, and investments play a crucial role in driving advancements and commercialization in the field of cell and gene therapy. The complex nature of these therapies requires multidisciplinary expertise and substantial financial resources, making strategic partnerships and investments essential for success. Here, we will explore the significance of collaborations, acquisitions, and investments in accelerating progress in the cell and gene therapy sector. For instance, in May 2021, Biogen and Ginkgo Bioworks formed a collaboration in the field of gene therapy. Their goal was to revolutionize the manufacturing process of recombinant adeno-associated virus (AAV)-based vectors, aiming to set a new industry standard.
Collaborations among pharmaceutical companies, biotech firms, academic institutions, and research organizations are common in the cell and gene therapy space. These collaborations bring together complementary expertise, resources, and technologies to tackle the challenges associated with the development, manufacturing, and commercialization of cell and gene therapies.
Strategic acquisitions are another means by which companies expand their capabilities and enhance their position in the cell and gene therapy market. Established pharmaceutical companies often acquire smaller biotech firms with promising pipelines or novel technologies. These acquisitions provide access to innovative therapies and specialized expertise, allowing larger companies to strengthen their product portfolio and accelerate the development and commercialization of new treatments.
Acquisitions in Cell & Gene Therapies in Q2 2021
|Acquisitions||Potential Deal Value (USD)|
|Sanofi Acquires Tidal Therapeutics||47,00,00,000|
|SparingVision Acquires GAMUT Therapeutics||Undisclosed|
|Athenex Acquires Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR- NKT Platform||18,50,00,000|
|Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities||35,00,00,000|
|Auris Medical Acquires RNA Therapeutics Company Trasir, Changes Name and Strategic Focus||Undisclosed|
|Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics||12,50,00,000|
|Avalon GloboCare to Acquire SenlangBio in All Stock Transaction||Undisclosed|
|uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy||29,83,00,000|
|Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune||Undisclosed|
|Danaher Pays $9.6B for Aldevron, Manufacturer of High-Quality Plasmid DNA, mRNA, and Proteins||9,60,00,00,000|
In recent years, there has been a surge in partnerships, acquisitions, and investments in the cell and gene therapy space. Major pharmaceutical companies have been actively engaging in collaborations with biotech firms, academic institutions, and research organizations to gain access to promising technologies and therapies.
Clinical trials play a vital role in the development and commercialization of cell and gene therapies. These trials are essential for assessing the safety and efficacy of these innovative treatments, gathering evidence for regulatory approvals, and establishing their value in clinical practice. Here, we will explore the significant role of clinical trials in the cell and gene therapy market. In the comparison between 2020 and 2021, there was a notable rise in the number of therapies in preclinical development. In 2020, there were 911 therapies in preclinical studies, while in 2021, the number increased to 1,223 therapies. This indicates significant growth and focus on preclinical research and development in the field.
Clinical trials are designed to evaluate the safety profile of cell and gene therapies in human subjects. These trials follow rigorous protocols and monitoring procedures to identify any potential adverse effects or complications associated with the treatment. Safety data collected from clinical trials help researchers and regulatory authorities make informed decisions about the risks and benefits of these therapies. Clinical trials also assess the effectiveness of cell and gene therapies in treating specific diseases or conditions. As of May 2021, there were around 1,745 therapies in various stages of development, ranging from preclinical to preregistration. These trials measure various endpoints, such as improvements in patient outcomes, reduction in symptoms, or disease progression. Efficacy data generated from well-designed and controlled clinical trials are crucial for demonstrating the therapeutic benefits of these treatments.
Clinical trials focus on addressing unmet medical needs and providing innovative solutions for patients who have limited treatment options. By demonstrating the efficacy of cell and gene therapies in challenging diseases or conditions, clinical trials generate interest and demand for these treatments. This drives market growth by creating new opportunities to meet the needs of patients who were previously underserved. Clinical trials are instrumental in driving market growth in the field of cell and gene therapy. They provide evidence of safety, efficacy, and economic value, support regulatory approvals, and facilitate market access and reimbursement. Clinical trials also foster collaboration, expand the indications for these therapies, and address unmet medical needs. With the continued advancement of clinical trial programs, the cell and gene therapy market is expected to grow significantly in the coming years.
FDA Approved Cell and Gene Therapies as of December 2022
|ADSTILADRIN||2022||Adenovirus||Ferring Pharmaceuticals A/S|
|CARVYKTI||2022||Cell (autologous, modified)||Janssen Biotech, Inc.|
|HEMGENIX||2022||AAV5||CSL Behring LLC, UniQure|
|SKYSONA||2022||Cell (autologous, modified)||bluebird bio, Inc.|
|ZYNTEGLO||2022||Cell (autologous, modified)||bluebird bio, Inc.|
|ABECMA||2021||Cell (autologous, modified)||Celgene Corporation, a Bristol-Myers Squibb Company|
|BREYANZI||2021||Cell (autologous, modified)||Juno Therapeutics, Inc., a Bristol-Myers Squibb Company|
|RETHYMIC||2021||Cell (allogeneic)||Enzyvant Therapeutics GmbH|
|STRATAGRAFT||2021||Cell (allogeneic)||Stratatech Corporation|
|TECARTUS||2020||Cell (autologous, modified)||Kite Pharma, Inc.|
|ZOLGENSMA||2019||AAV9||Novartis Gene Therapies, Inc.|
|HPC, Cord Blood - MD Anderson Cord Blood Bank||2018||Cell (allogeneic)||MD Anderson Cord Blood Bank|
|KYMRIAH||2017||Cell (autologous, modified)||Novartis Pharmaceuticals Corporation|
|LUXTURNA||2017||AAV2||Spark Therapeutics, Inc.|
|YESCARTA||2017||Cell (autologous, modified)||Kite Pharma, Inc.|
|CLEVECORD||2016||Cell (allogeneic)||Cleveland Cord Blood Center|
|HPC, Cord Blood - LifeSouth||2016||Cell (allogeneic)||LifeSouth Community Blood Centers, Inc.|
|HPC, Cord Blood - Bloodworks||2016||Cell (allogeneic)||Bloodworks|
|MACI||2016||Cell (autologous, expanded)||Vericel Corp.|
|IMLYGIC||2015||HSV-1||BioVex, Inc., a subsidiary of Amgen Inc.|
|ALLOCORD||2013||Cell (allogeneic)||SSM Cardinal Glennon Children's Medical Center|
|DUCORD||2012||Cell (allogeneic)||Duke University School of Medicine|
|GINTUIT||2012||Cell (allogeneic)||Organogenesis Inc.|
|HPC, Cord Blood||2012||Cell (allogeneic)||Clinimmune Labs, University of Colorado Cord Blood Bank|
|HEMACORD||2011||Cell (allogeneic)||New York Blood Center|
|LAVIV||2011||Cell (autologous, expanded)||Fibrocell Technologies|
|PROVENGE||2010||Cell (autologous, activated/expanded)||Dendreon Corp.|
The North America region holds a prominent position in the global cell and gene therapy market. With its advanced healthcare infrastructure, strong regulatory framework, and significant investments in research and development, North America has become a hub for innovation and commercialization in this field.
The cell and gene therapy market in North America is experiencing significant growth due to the high prevalence of chronic diseases such as cancer, cardiovascular diseases, and genetic disorders. These conditions have created a demand for personalized and effective treatment options. Cell and gene therapies have emerged as promising solutions, addressing the root causes of these diseases and offering new possibilities for treatment and management.
The presence of leading pharmaceutical and biotechnology companies in North America further strengthens the market. These companies have been at the forefront of research and development in cell and gene therapies, investing heavily in clinical trials and infrastructure. Their expertise, combined with collaborations with academic institutions and research organizations, has accelerated the translation of scientific discoveries into commercial products. The regulatory landscape in North America has also been supportive of the cell and gene therapy market. The U.S. Food and Drug Administration (FDA) has established expedited regulatory pathways, such as the Regenerative Medicine Advanced Therapy (RMAT) designation and the Fast Track designation, to facilitate the development and approval of promising therapies.
The United States, in particular, dominates the cell and gene therapy market in North America. The country has a well-established biotechnology sector, a favorable regulatory environment, and a large patient population, making it an attractive market for cell and gene therapy companies. Several key players in the field are headquartered in the United States, driving innovation and market expansion.
The Asia Pacific region is emerging as a promising market for cell and gene therapy. With its large and diverse population, increasing prevalence of chronic diseases, and growing investments in healthcare infrastructure, the region offers significant opportunities for the development and commercialization of cell and gene therapies.
Several countries in the Asia Pacific region have shown strong commitment to advancing cell and gene therapies through supportive regulatory frameworks and government initiatives. For example, Japan has implemented the Act on the Safety of Regenerative Medicine, which aims to accelerate the approval process for regenerative medicine products. China has also made significant investments in the field, launching the Made in China 2025 initiative to promote the development of innovative therapies.
Innovative therapies play a crucial role in the growth of the cell and gene therapy market. These therapies offer novel approaches to treating diseases and conditions by harnessing the power of cells and genes.
Innovative cell and gene therapies have the potential to address unmet medical needs for a wide range of diseases and conditions. They provide new treatment options for patients who have limited or no effective therapies available. By targeting diseases at the cellular and genetic levels, these therapies offer the potential for improved outcomes and quality of life for patients.
Cell and gene therapies have the ability to deliver personalized medicine approaches. They can be tailored to individual patients based on their genetic profile, disease characteristics, or other specific factors. Personalized therapies have the potential to be more targeted and effective, leading to better treatment outcomes. This shift towards personalized medicine is a significant driver for market growth. Innovative cell and gene therapies have shown promising results in the treatment of various types of cancers. For example, CAR T cell therapies have demonstrated remarkable success in certain forms of leukemia and lymphoma. These therapies involve modifying a patient's own immune cells to recognize and target cancer cells. Their potential to achieve long-lasting remission and even cure in some cases has revolutionized cancer treatment and contributed to market growth.
Innovations in gene editing technologies, such as CRISPR-Cas9, have opened up new possibilities for the treatment of genetic disorders. These technologies allow precise modification of genes, offering potential solutions for inherited diseases with a genetic component. Gene editing can correct genetic defects, restore normal gene function, or enhance therapeutic outcomes. The development and application of gene editing technologies have propelled the growth of the cell and gene therapy market. Regulatory agencies have recognized the potential of cell and gene therapies and have implemented expedited pathways to facilitate their development and approval. This regulatory support has encouraged investment in research and development, leading to the emergence of innovative therapies. Regulatory frameworks that prioritize patient safety while expediting the approval process have contributed to the growth of the market.
The cell and gene therapy market has experienced remarkable growth and progress in recent years, holding immense potential for transforming healthcare with personalized and targeted therapies. Several key players dominate the competitive landscape in this field. To gain a larger share of the market, players are using strategies like investments, alliances, acquisitions, and mergers.
Some of the major market players in the Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., CORESTEM Inc., Dendreon Pharmaceuticals LLC., Helixmith Co. Ltd., JCR Pharmaceuticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, and Pfizer Inc.
Segments Covered in the Report
By Therapy Type
By Therapeutic class
By Delivery Method
Namrata Bukshet is a highly accomplished market researcher with a strong background in healthcare. She holds a Bachelor of Pharmacy degree and a Post Graduate Diploma in Pharmaceutical Management. Passionate about understanding consumer behavior and market trends, Namrata has conducted extensive research on lifestyle disorders and presented a paper on \"E-Biz: India\'s 1st G2B Online Portal\" at an international conference. Her expertise and insights continue to shape the field of market research and pharmaceuticals, making her a sought-after professional in the industry. With her commitment to understanding the \"why\" behind consumer behaviors, Namrata continues to make valuable contributions to the field of market research.